第二阶段

我们是谁

  • 1 月 12, 2024
    联合免疫疗法方案的 I/II 期研究：治疗转移性结直肠癌 (mCRC) 的联合免疫疗法方案：SX-682、TriAdeno 疫苗、雷替凡利单抗和 IL-15 激动剂 N-803 (STAR15)
  • 1 月 10, 2024
    评估INCB099280对免疫检查点抑制剂无效的特定实体瘤患者的作用的研究
  • 1 月 10, 2024
    PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
  • 1 月 9, 2024
    KN035 for dMMR/MSI-H Advanced Solid Tumors
  • 1 月 9, 2024
    Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )
  • 1 月 9, 2024
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
  • 1 月 9, 2024
    A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )
  • 1 月 9, 2024
    NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
  • 1 月 9, 2024
    Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
  • 1 月 9, 2024
    Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer